CALR and myeloproliferative disorder: In conclusion, immunohistochemistry is readily available in the majority of diagnostic laboratories and the detection of CALR mutations by the CAL2 antibody represents a valuable supplement to traditional mutation testing and can help to facilitate the timely, appropriate selection and treatment of patients with myeloproliferative neoplasms with targeted therapies.